Equities research analysts expect that Charles River Laboratories (NYSE:CRL) will post earnings of $1.26 per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Charles River Laboratories’ earnings, with the highest EPS estimate coming in at $1.28 and the lowest estimate coming in at $1.24. Charles River Laboratories reported earnings per share of $1.29 in the same quarter last year, which would suggest a negative year over year growth rate of 2.3%. The business is scheduled to issue its next quarterly earnings results before the market opens on Wednesday, May 9th.
According to Zacks, analysts expect that Charles River Laboratories will report full-year earnings of $5.77 per share for the current fiscal year, with EPS estimates ranging from $5.75 to $5.80. For the next year, analysts anticipate that the business will post earnings of $6.58 per share, with EPS estimates ranging from $6.50 to $6.71. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Charles River Laboratories.
Charles River Laboratories (NYSE:CRL) last announced its quarterly earnings data on Tuesday, February 13th. The medical research company reported $1.40 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.14. Charles River Laboratories had a return on equity of 26.14% and a net margin of 6.64%. The business had revenue of $478.50 million during the quarter, compared to analyst estimates of $475.02 million. During the same period in the prior year, the company earned $1.21 earnings per share. Charles River Laboratories’s revenue was up 2.5% compared to the same quarter last year.
In other Charles River Laboratories news, insider Birgit Girshick sold 9,893 shares of the stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $109.10, for a total transaction of $1,079,326.30. Following the sale, the insider now owns 26,470 shares in the company, valued at $2,887,877. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director George M. Milne, Jr. sold 7,740 shares of the stock in a transaction on Friday, March 9th. The stock was sold at an average price of $115.00, for a total value of $890,100.00. Following the sale, the director now owns 36,760 shares in the company, valued at approximately $4,227,400. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 193,658 shares of company stock worth $6,913,383. Company insiders own 2.10% of the company’s stock.
Several large investors have recently bought and sold shares of CRL. Tower Research Capital LLC TRC raised its position in shares of Charles River Laboratories by 1,071.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,054 shares of the medical research company’s stock worth $115,000 after buying an additional 964 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Charles River Laboratories by 69.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after buying an additional 548 shares in the last quarter. ETRADE Capital Management LLC purchased a new stake in shares of Charles River Laboratories in the fourth quarter worth $218,000. Advisor Group Inc. raised its position in shares of Charles River Laboratories by 31.5% in the fourth quarter. Advisor Group Inc. now owns 2,023 shares of the medical research company’s stock worth $221,000 after buying an additional 485 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Charles River Laboratories in the third quarter worth $261,000. Hedge funds and other institutional investors own 99.83% of the company’s stock.
Shares of NYSE CRL opened at $107.25 on Friday. Charles River Laboratories has a 1-year low of $86.66 and a 1-year high of $119.05. The firm has a market cap of $5,029.84, a price-to-earnings ratio of 20.08, a PEG ratio of 1.59 and a beta of 0.68. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.78 and a quick ratio of 1.54.
Charles River Laboratories Company Profile
Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.